Tokyo, May 31, 2018- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.) today announced that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its own shares under Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

Particulars

  1. Reasons for the acquisition of own shares
    Shareholder return and improvement of capital efficiency

  2. Contents of acquisition
    (1) Class of shares to be acquired:    Common stock of the Company
    (2) Total number of shares to be acquired:    Up to 60 million shares
         (The percentage compared to the total number of shares outstanding: 3.04 %)
    (3) Aggregate amount of acquisition cost:    Up to 100 billion yen
    (4) Period of acquisition:   From June 1, 2018 to September 20, 2018

    (Reference) 
    The status of treasury shares as of March 31, 2018:
     Total number of shares outstanding:    1,976,152,409 shares
     Number of treasury shares:                       92,670,766 shares